Skip Navigation

Chronic Idiopathic Constipation

printer friendly version


A double-blind, randomized, placebo-controlled, phase 3 trial in patients with chronic idiopathic constipation to demonstrate the efficacy and safety of elobixibat 5 mg and 10 mg for 26 weeks – Trial 000079, Echo 1

IRB# HUM00078625; This study is sponsored by Ferring Pharmaceticals.

Research Drug

Elobixibat interrupts the enterohepatic circulation of bile acids (BA) by decreasing intestinal BA reabsorption, which results in an increased BA load to the colon, which is expected to benefit patients with constipation.

Study Description

A total of 840 patients will be included who meet the Rome III criteria for chronic idiopathic constipation will participate in this trial worldwide. Randomized subjects will receive one of three study drug treatments: 5 mg, 10 mg, 30 mg; and a fourth group will receive the placebo. Total participation is approximately 30 weeks and requires up to 11 visits. Interested participants may roll over to a one-year open-label extension study. Procedures include: physical exam, vital signs, EKG, and clinical lab tests.

Subject Eligibility

Compensation: $50 per visit

Principal Investigator: Richard Saad, MD

Study Coordinator: Lina E-mail: LNahlawi@med.umich.edu, Telephone: (734) 936-2761